Abstract | BACKGROUND: METHODS: Randomized, double-blind, placebo-controlled design. Twenty-three patients with mild-to-moderate Alzheimer disease and apnea-hypopnea index (AHI) > 5/h were allocated to two groups: donepezil treated (n = 11) and placebo treated (n = 12). Polysomnography and cognitive evaluation using Alzheimer disease assessment scale-cognitive (ADAS-cog) subscale were performed at baseline and after 3 months. Cognitive and sleep data were analyzed using analysis of variance. RESULTS: AHI and oxygen saturation improved significantly after donepezil treatment compared to baseline and placebo (p < 0.05). Rapid eye movement (REM) sleep duration increased after donepezil treatment (p < 0.05). ADAS-cog scores improved after donepezil treatment, although they did not correlate with REM sleep increase and sleep apnea improvement (p < 0.01). CONCLUSIONS:
Donepezil treatment improved AHI and oxygen saturation in patients with Alzheimer disease. Treatment also increased REM sleep duration and reduced ADAS-cog scores. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00480870.
|
Authors | Walter Moraes, Dalva Poyares, Lucia Sukys-Claudino, Christian Guilleminault, Sergio Tufik |
Journal | Chest
(Chest)
Vol. 133
Issue 3
Pg. 677-83
(Mar 2008)
ISSN: 0012-3692 [Print] United States |
PMID | 18198262
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Indans
- Nootropic Agents
- Piperidines
- Donepezil
|
Topics |
- Aged
- Aged, 80 and over
- Alzheimer Disease
(complications, drug therapy, psychology)
- Donepezil
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Indans
(therapeutic use)
- Male
- Middle Aged
- Nootropic Agents
(therapeutic use)
- Piperidines
(therapeutic use)
- Polysomnography
- Psychometrics
(methods)
- Sleep Apnea, Obstructive
(complications, drug therapy, physiopathology)
- Sleep, REM
(physiology)
- Treatment Outcome
|